The fact that systemic application of CPP16-mediated MCOLN1 gene transfer was efficacious in the mouse model, as we showed in this study, provides additional evidence supporting the further development of such therapy for MLIV patients. Here, MCOLN1 is linked to mucolipidosis type IV.